scispace - formally typeset
R

Rachel J. Rybak

Researcher at University of Alabama at Birmingham

Publications -  7
Citations -  476

Rachel J. Rybak is an academic researcher from University of Alabama at Birmingham. The author has contributed to research in topics: In vivo & Thymidine kinase. The author has an hindex of 6, co-authored 7 publications receiving 472 citations.

Papers
More filters
Journal ArticleDOI

A new animal model of binge eating: Key synergistic role of past caloric restriction and stress

TL;DR: In this article, a group of young female rats were cycled through a restriction period (4 days of 66% of control food intake) followed by 6 days of free feeding prior to being stressed by acute foot shock.
Journal ArticleDOI

The role of palatable food and hunger as trigger factors in an animal model of stress induced binge eating.

TL;DR: In this article, the authors developed an animal model of binge eating in sated rats that is evoked by stress, but only in rats with a history of caloric restriction and only if highly palatable food (HPF) is available after stress.
Journal ArticleDOI

Effective treatment of murine cytomegalovirus infections with methylenecyclopropane analogues of nucleosides.

TL;DR: A number of new nucleoside analogues with a Z- or E-methylenecyclopropane structure exhibited significant activity against human and murine cytomegaloviruses (HCMV, MCV) in tissue culture that was generally comparable to, or greater than, 9-[(1-3-dihydroxy-2-propoxy)methyl]guanine (ganciclovir, GCV).
Journal Article

Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections.

TL;DR: Results indicate that both the SCID-hu retinal and SCid-hu thy/liv implant models are useful for determining in vivo activity against HCMV, and appear to be predictive of efficacy for both ocular and systemic infections in humans.
Journal ArticleDOI

Synthesis and antiviral evaluation of 1-O-hexadecylpropanediol-3-P-acyclovir: efficacy against HSV-1 infection in mice.

TL;DR: 1-O-hexadecylpropanediol-3–P-acyclovir, an orally bioavailable lipid prodrug of acyclovirs evaluated it for in vitro and in vivo activity against herpes simplex virus infections and had somewhat higher activity in cytomegalovirus infection in vitro.